Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.

The F-111 concept was introduced in 1960 for the Air Force. The U.S. Navy opted not to acquire it and stopped the program. The Royal Australian Air Force had F-111s in service until 2010, but they ...

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...

Summary and Most Important Points: The F-111 Aardvark, a pioneering supersonic, multirole jet, served the U.S. Air Force for ...

“Aardvark’s breakthrough is not just about speed, it’s about access,” said Dr Scott Hosking, Director of Science and Innovation for Environment and Sustainability at the Alan Turing Institute.

Aardvark Weather operates at 1.5-degree resolution, meaning each box in its grid covers 1.5 degrees of latitude and 1.5 degrees of longitude. For comparison, the GFS uses a 0.25-degree grid.

Aardvark late Wednesday priced 5.88 million shares at $16 each, which was the low end of the price range set in preliminary IPO terms last week. Those shares will trade on the Nasdaq under the ...

An aardvark is approached by a spotted hyena while digging a burrow with its powerful fingernails. To Martin and Chris' surprise, aardvark claws aren't only used for digging, but as a defense ...

Aardvark Sports Shop in Bethlehem hosts Striding with Pride in collaboration with Allentown’s Bradbury-Sullivan LGBT Community Center and On Running shoe brand Wednesday, June 18, 2025, in Be… ...

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations.. The company’s 5.9 million shares will be offered at $16 ...

--Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of ...

Aardvark has yet to set the value of its planned IPO but said in its Securities and Exchange Commission filing Jan. 23 that it expects to use the proceeds to “advance the clinical development of ...